Literature DB >> 25240411

Interventional pulmonologist perspective: treatment of malignant pleural effusion.

Andrew J Sweatt1, Arthur Sung.   

Abstract

OPINION STATEMENT: The management of known malignant pleural effusions focuses around the initial thoracentesis and subsequent objective and subjective findings. A completely reexpanded lung after fluid removal and with symptomatic improvement predicts successful pleurodesis. Pleurodesis method depends on center expertise as well as patient preference. Medical thoracoscopy does not require the operating room setting and is performed on the spontaneously breathing patient with similar success rate to surgical thoracoscopy in the appropriately selected patients. However, it is not widely available. Talc insufflation is preferred for even distribution of sprayed particles to pleural surfaces. Most often, patients can be discharged home within 24 to 48 hours after continuous chest tube suction. Indwelling pleural catheter has become popular given the ease of insertion and patient centered home drainage. Coordinated care with good patient and family education and support is paramount to maximizing the beneficial potential of the catheter. Complications are minimal, and catheters are easily removed if patients can no longer benefit from drainage, or if pleurodesis has occurred. In the setting of trapped lung as a result of visceral pleura encasement from tumor, indwelling catheter can still be useful if the patient improves with thoracentesis. However, if no subjective improvement is seen after thoracentesis for trapped lung, then no procedure is recommended and other modes of palliation should be sought.

Entities:  

Mesh:

Year:  2014        PMID: 25240411     DOI: 10.1007/s11864-014-0312-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  96 in total

1.  Pleural effusion; a statistical study of 436 patients.

Authors:  E C LEUALLEN; D T CARR
Journal:  N Engl J Med       Date:  1955-01-20       Impact factor: 91.245

Review 2.  Medical thoracoscopy: rigid thoracoscopy or flexi-rigid pleuroscopy?

Authors:  Kim Hoong Yap; Martin J Phillips; Y C Gary Lee
Journal:  Curr Opin Pulm Med       Date:  2014-07       Impact factor: 3.155

Review 3.  Pleuroscopy for diagnosis and therapy for pleural effusions.

Authors:  Gaetane Michaud; David M Berkowitz; Armin Ernst
Journal:  Chest       Date:  2010-11       Impact factor: 9.410

4.  Video-assisted thoracoscopic (VATS) pleurodesis for malignant effusion: an Australian teaching hospital's experience.

Authors:  Dean Trotter; Ahmad Aly; Lyndon Siu; Simon Knight
Journal:  Heart Lung Circ       Date:  2005-06       Impact factor: 2.975

5.  Primary carcinoma of the lung. A review of 417 histologically proved cases.

Authors:  S Cohen; S A Hossain
Journal:  Dis Chest       Date:  1966-01

6.  Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients.

Authors:  Li-Han Hsu; Thomas C Soong; An-Chen Feng; Mei-Ching Liu
Journal:  J Thorac Oncol       Date:  2006-06       Impact factor: 15.609

7.  Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.

Authors:  Steffen Kolschmann; Arndt Ballin; Adrian Gillissen
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

Review 8.  Pleurodesis for malignant pleural effusions.

Authors:  P Shaw; R Agarwal
Journal:  Cochrane Database Syst Rev       Date:  2004

9.  A comparison of rotation and nonrotation in tetracycline pleurodesis.

Authors:  S R Dryzer; M L Allen; C Strange; S A Sahn
Journal:  Chest       Date:  1993-12       Impact factor: 9.410

10.  The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions.

Authors:  D Sears; S I Hajdu
Journal:  Acta Cytol       Date:  1987 Mar-Apr       Impact factor: 2.319

View more
  2 in total

1.  Simple intrapleural hyperthermia at thoracoscopic exploration to treat malignant pleural effusion.

Authors:  Youngkyu Moon; Kyung Soo Kim; Jae Kil Park
Journal:  J Cardiothorac Surg       Date:  2015-10-28       Impact factor: 1.637

2.  Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.

Authors:  Hong Tao; Qiyi Meng; Mingzhi Li; Liang Shi; Junfang Tang; Zhe Liu
Journal:  Thorac Cancer       Date:  2018-01-03       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.